New call-to-action
New call-to-action
New call-to-action

FPWR Blog

FPWR

Recent Posts

Reflecting on 2024: A Year of Progress & Promise for the PWS Community

As 2024 draws to a close, we at the Foundation for Prader-Willi Research (FPWR) are reflecting on a year filled with progress, promise, and hope. This year’s achievements wouldn’t have been possible without the incredible dedication of our community—...

Topics: Research

Recap of the PWS-CLIC Meeting in Atlanta

The PWS-Clinical Investigation Collaborative (PWS-CLIC), a network of PWS clinical experts formally established in 2021 and supported by FPWR, held their annual meeting in Atlanta, Georgia, in conjunction with the FPWR Research Symposium and Family C...

Topics: Research

United in Hope: 2025 Global Prader-Willi Syndrome Conference

We are excited to announce that the 2025 "United in Hope" conference will be held in collaboration with the International Prader-Willi Syndrome Organisation (IPWSO), the Prader-Willi Syndrome Association | USA (PWSA | USA), and the Foundation for Pra...

FDA Determines No Need For Advisory Committee Meeting At This Time

Soleno Therapeutics announced today that the U.S. Food and Drug Administration (FDA) Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (di...

Select Sessions from our 2024 Research Symposium and Family Conference Now Available

We're excited to announce that select sessions from our recent PWS Research Symposium and Family Conference are now available to watch! This year’s event brought together leading experts, researchers, and families from around the world to explore the...

New Study Highlights the Severe Impact of COVID-19 for Individuals with PWS

As the COVID-19 pandemic continues to evolve, researchers are working hard to understand how the virus affects individuals with Prader-Willi syndrome (PWS). A recent study by FPWR Grant Recipient Dr. James Luccarelli and colleagues from the Massachus...

Topics: Research

FDA Accepts DCCR Filing and Grants Priority Review

Soleno Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) and granted priority review for DCCR (Diazoxide Choline Controlled-Release), a treatment for patients with Prader-Willi...

Exploring Type I and II Deletions in Prader-Willi: Cell-Level Insights

70% of cases of Prader-Willi syndrome are associated with a “deletion” of 5,000–6,000 missing base pairs (bp) of DNA on the paternally inherited copy of chromosome 15. What are the biological consequences of the larger 6,000-bp deletion (typically ca...

Topics: Genetics and Imprinting, Research

The Matesevac Family Welcomes You to Atlanta this September!

A special contribution by guest blogger Lisa Matesevac. Welcome to the ATL! We are thrilled that our city will host the annual Foundation for Prader-Willi Research Symposium and Family Conference in September 2024! Together with my family and the Geo...

Topics: Parents